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Abstract We examined the neuroprotective efficacy of
docosahexaenoic acid (DHA), an omega-3 essential fatty
acid family member, in acute ischemic stroke; studied the
therapeutic window; and investigated whether DHA ad-
ministration after an ischemic stroke is able to salvage the
penumbra. In each series described below, SD rats
underwent 2 h of middle cerebral artery occlusion (MCAo).
In series 1, DHA or saline was administered i.v. at 3, 4, 5,
or 6 h after stroke. In series 2, MRI was conducted on
days 1, 3 and 7. In series 3, DHA or saline was
administered at 3 h, and lipidomic analysis was conducted
on day 3. Treatment with DHA significantly improved
behavior and reduced total infarct volume by a mean of
40% when administered at 3 h, by 66% at 4 h, and by 59%
at 5 h. Total lesion volumes computed from T2-weighted
images were reduced in the DHA group at all time points.
Lipidomic analysis showed that DHA treatment potentiates
neuroprotectin D1 (NPD1) synthesis in the penumbra 3 days
after MCAo. DHA administration provides neurobehavioral
recovery, reduces brain infarction and edema, and activates
NPD1 synthesis in the penumbra when administered up to
5 h after focal cerebral ischemia in rats.
Keywords Focal ischemia.Magnetic resonance imaging.
Neuroprotection.Animal models
Introduction
Each year, over 15 million people worldwide suffer a
stroke, many of which are ischemic [1]. Thrombolysis is the
only treatment for ischemic stroke, but due to its narrow
therapeuticwindowandcomplexityofadministration,only3–
5% of patients benefit from this therapy [2]. Focal cerebral
ischemia produces a brain lesion composed of an irreversibly
injured core and a peripheral zone (penumbra), where tissue
is damaged but potentially salvageable [3]. The penumbra
has a limited life span and appears to undergo irreversible
damage within a few hours unless reperfusion is initiated
and/or neuroprotective therapy is administered [4].
Docosahexaenoic acid (DHA; 22:6, n-3) is an essential
omega-3 fatty acid concentrated in membrane phospholipids
of the central nervous system [5]. DHA is a natural element
of our diet and is found in cold water fatty fish, including
salmon, tuna, mackerel, sardines, shellfish, and herring.
DHA has been shown to be involved in brain and retinal
development, aging, memory formation, synaptic membrane
function, photoreceptor biogenesis and function, and neuro-
protection [6–8]. The recent identification of the protective
docosanoid neuroprotectin D1 (NPD1; 10R,17S-dihydroxy-
docosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic acid) in brain is-
chemia reperfusion [9], as well as in neural cells exposed to
oxidative stress [10–12], has uncovered a key survival-
signaling event leading to neuroprotection. NPD1 is a
pleiotropic modulator of inflammation resolution [13]. More-
over several reports show that DHA is protective in ischemia
[3, 7] andinspinalcordinjury[14]. However, the mechanism/s
and bioactive mediator/s involved - and particularly whether
or not these mechanisms/mediators target the salvageable
area of the stroke penumbra - have not yet been defined. In
addition, the effect of systemic administration of DHA on the
ischemic brain penumbra has not been explored.
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medium doses improves neurological and histological
outcome following focal cerebral ischemia [15]. The
present study investigated the therapeutic window of
DHA treatment in focal cerebral ischemia in rats. In
addition, we studied whether administration of DHA after
an ischemic stroke is able to salvage the penumbra. We
used non-invasive magnetic resonance imaging (MRI) and
LC-MS/MS-mediator lipidomic analysis in conjunction
with behavioral, histological, and immunostaining methods
to expand our understanding of this novel therapeutic
approach. No prior studies have used MRI to evaluate the
temporal effects of DHA treatment on brain ischemia.
Materials and Methods
Surgical Preparation
All studies were approved by the Institutional Animal Care
and Use Committees of the Louisiana State University
Health Sciences Center and Loma Linda University. Male
Sprague–Dawley rats (Charles River Lab., Wilmington,
MA) weighing 279–340 g were fasted overnight but
allowed free access to water. Anesthesia was induced
with 3.5% isoflurane in a mixture of 70% nitrous oxide
and 30% oxygen. All rats were orally intubated and
mechanically ventilated. Temperature probes were
inserted into the rectum and the left temporalis muscles
to maintain temperatures at 36–37°C during surgical
procedures. The right femoral artery and vein were
catheterized for blood sampling for arterial gases, pH,
plasma glucose, and drug infusion.
Transient Middle Cerebral Artery Occlusion
Rats underwent 2 h of right middle cerebral artery
occlusion (MCAo) by an intraluminal filament, coated
with poly-L-lysine as previously described [16]. After 2 h
of MCAo, rats were reanesthetized with the same
anesthetic combination and intraluminal sutures were
carefully removed.
Behavioral Tests
Behavioral tests were performed by an observer blinded
to the treatment groups at 60 min (during MCAo) and
then on days 1, 2, 3, and 7 after MCAo. The battery
consisted of the postural reflex test and the forelimb-
placing test to visual, tactile, and proprioceptive stimuli.
Neurological function was graded on a scale of 0–12
(normal score=0; maximum score=12), as previously
described [16].
Treatment
In each series described below, rats underwent 2 h of
MCAo. DHA (5 mg/kg) was dissolved in saline and
administered intravenously at a constant rate over 3 min
using an infusion pump according the study protocol.
Vehicle-treated rats received an intravenous infusion of a
comparable volume of 0.9% sodium chloride.
Study Protocols
In series 1 (therapeutic window study), DHA was admin-
istered i.v. at either 3, 4, 5 or 6 h after onset of stroke (n=6–
7 per group). Vehicle group received saline at 3 h after
onset of stroke. Behavioral testing was conducted on days 1,
2, 3, and 7 followed by histopathology on day 7. In series 2
(MRI study), DHA (n=5) or saline (n=4) was administered
at 3 h after onset of stroke and MRI was conducted on
days 1, 3, and 7. In series 3 (lipidomic study), DHA or
saline was administered at 3 h (n=5–6 per group) and
lipidomic analysis was conducted on day 3.
Magnetic Resonance Imaging
Rats were anesthetized with isoflurane and imaged on a
Bruker Avance 4.7T MRI (Bruker Biospin, Billerica MA)
as previously described [17]. A thermostat-controlled
heated water cushion maintained body temperature at 36–
37°C and respiration was monitored using a pneumatic
cushion (Biopac Model 150, Goleta CA).
Image Analysis
T2 and apparent diffusion coefficient (ADC) maps were
computed from T2-weighted imaging (T2WI) and
diffusion-weighted imaging (DWI), respectively, as previ-
ously described [17]. Three-dimensional images were
obtained to delineate the volumetric development of
ischemic injury. Analysis included extraction of lesion,
non-lesioned brain, and total brain volumes. Region of
interest (ROI) was drawn semi-automatically on each slice
and manually checked. From these ROIs, the lesion volume
was calculated over all slices (volume of lesion/total brain
volume) and expressed as a percentage. Penumbral tissues
were estimated by evaluating both T2 and DWI lesion
volumes and comparing these to the final imaging time
point, as we have previously described [17].
Histopathology and Immunostaining
Animals were perfused with 4% paraformaldehyde on
day 7, and brains were removed and embedded in a gelatin
matrix using MultiBrain™ Technology (NeuroScience
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Coronal sections were stained with thionine (Nissl), and
immunohistochemical procedures were performed on the
adjacent sections. To quantitate infarct volume, histological
sections were digitized at nine standardized coronal levels
and analyzed (MCID™ Core imaging software, Linton,
Cambridge, UK) as previously described [16]. Infarct
volume was calculated as the integrated product of cross-
sectional area and intersection distance and corrected for
brain swelling. The following antibodies were used: glial
fibrillary acid protein (GFAP, Santa Cruz, SDS Biosciences,
Sweden) to label reactive astrocytes, Cd68/ED-1 (Serotec,
Raleigh, NC) for activated microglia/microphages, and
neuron-specific nuclear protein (NeuN, Chemicon/Milli-
pore, Billerica, MA). The number of GFAP, ED-1, and
NeuN-positive cells were counted (Zeiss Axio Imager
4.6.3) in the cortex and striatum at the level of the central
lesion (bregma level −0.3 mm; magnification ×40). Data
were expressed as numbers of positive cells per high-power
microscopic field. Brain slices were imaged on a Zeiss
LSM-510 Meta laser confocal microscope with a ×10
objective (Zeiss Plan-NEOFLUAR 10×/0.3). Fluorophore
visualization (excitation/emission capture) was achieved as
follows: GFAP, DyLight 488 (488 nm/505–530 nm, green);
and ED1, DyLight 594 (594 nm/603–636 nm, red). The
image resolution was set to 2.26 μm/pixel and the cubic
voxel dimension was 129.5 μm. Computer-generated
MosaiX-processed images of Nissl, GFAP, ED-1, and
GFAP/ED-1 double staining from saline and DHA rats
were generated.
Lipidomic Analysis
Rats were perfused with cold ice saline at 3 days after
stroke. For each animal, the brain was removed and
blocked into two segments that included the bregma levels
+2.7 and −0.3 mm. Next, coronal blocks were divided into
right and left hemispheres and cut into two regions (one for
the cortex and one for the striatum). Neuroprotectin D1
(NPD1), the DHA-derived stereoselective lipid mediator,
and 17-HDHA (a marker of 17H(p)DHA, the short lived-
NPD1 precursor) were isolated from the penumbra as
previously described [9] using a liquid chromatography-
photodiode array ultraviolet detector-LTQ linear ion trap
mass spectrometer (LC-UV-MS/MS; Thermo, Waltham,
MA) equipped with an LC column (150 mm×2 mm×
5 μm, LUNA C18, Phenomenex, Torrance, CA).
Statistical Analysis
Data are presented as mean values ± SEM. Repeated-
measures analysis of variance (ANOVA) followed by
Bonferroni procedures to correct for multiple comparisons
were used for intergroup comparisons of neurobehavioral
scores over time and infarct areas across coronal levels.
Two-tailed Student'st tests were used for two-group
comparisons. Differences at p<0.05 were considered
statistically significant.
Results
Rectal and cranial (temporalis muscle) temperatures, arterial
blood gases, plasma glucose, and hematocrit showed no
significant differences among groups. There were no adverse
behavioral side effects observed after DHA administration to
rats in the present study.
Series 1: Therapeutic Window Study
Neurological deficits were reduced by DHA, even when
treatment was initiated as late as 5 h after MCAo onset
(Fig. 1a): day 1 (DHA: 3 h, 7.7±0.2; 4 h, 6.9±0.7; 5 h,
7.2±0.5; and 6 h, 8.3±0.2 vs. Saline: 9.8±0.2; p<0.01),
day 2 (DHA: 3 h, 7.7±0.2; 5 h, 6.5±0.8; and 6 h, 7.8±0.3 vs.
Saline: 9.8±0.2; p< 0 . 0 1 ) ,d a y3( D H A :3h ,7 . 1 ± 0 . 6 ;5h ,
6.0±1.0; and 6 h, 8.2±0.4 vs. Saline: 9.7±0.2; p<0.003)and
day 7 (DHA: 3 h, 6.0±0.6; 4 h, 5.7±1.0; 5 h, 5.5±0.9 vs.
Saline: 9.0±0.3; p<0.0004). DHA-mediated protection was
extensive in the frontal–parietal cortex (tissue salvage, 49%
(p<0.02), 77% (p<0.002), and 71% (p<0.004), respectively
for 3 h, 4 h and 5 h; Fig. 1b) and across multiple coronal
levels. DHA administration did not affect the subcortical
infarct, except when it was infused at 4 h (p<0.01; Fig. 1c).
Total infarct volume, corrected for brain swelling, was
reduced by 40% (p<0.02) when DHA was administered at
3h ,b y6 6 %( p<0.001) at 4 h, and by 59% (p<0.003)at5 h
(Fig. 1d). The brains of saline-treated rats exhibited a
consistent pannecrotic lesion involving both cortical and
subcortical (mainly striatal) regions of the right hemi-
sphere, characterized microscopically by destruction of
neuronal, glial, and vascular elements. In contrast, infarct
size was dramatically reduced in rats treated with DHA
a t3 ,4 ,a n d5ha f t e ro n s e to fi s c h e m i a ,b u tn o ti n
6-h group (Fig. 1e).
Saline-treated rats showed extensive neuronal loss,
GFAP-positive reactive astrocytes outlining the lesion
territory, and massive ED-1-positive microglia/macro-
phage infiltration (Fig. 1f, top). In contrast, DHA-
attenuated damage as well as decreased ED-1-positive
microglia/macrophages and increased GFAP-positive re-
active astrocytes (Fig. 1f,b o t t o m ) .F i g u r e2 presents
GFAP-, ED-1-, and NeuN-positive cell counts. DHA
treatment significantly decreased ED-1 (p<0.01) and
increased NeuN (p<0.01) and GFAP-positive (p<0.005)
cell counts.
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Fig. 1 Therapeutic window study: a Neurological score (normal
score=0; maximum score=12) was improved after DHA administration
when administered 3, 4, and 5 h after onset of stroke. Cortical (b),
subcortical (c), and total corrected infarct volumes (d) on day 7. DHA
reduced cortical and total infarct volumes when administered 3, 4, and
5 h after stroke. Data are means ± SEM. Asterisk, significantly different
from saline (p<0.05; repeated-measures ANOVA followed by Bonferroni
tests). e Computer-generated MosaiX-processed images of Nissl stained
paraffin-embedded brain sections from rats treated with saline or DHA
at 3, 4, 5, and 6 h after the onset of ischemia. Saline-treated rat
shows large cortical and subcortical infarction. In contrast, rats
t r e a t e dw i t hD H Aa t3 ,4 ,a n d5hs h o wl e s se x t e n s i v ed a m a g e ,
mostly in the subcortical area. DHA-treated rat at 6 h shows infarct
involving cortical and subcortical regions. f Computer-generated
MosaiX-processed images of GFAP (green), ED-1 (red), and GFAP/
ED-1 double staining (overlay)o nd a y7a f t e r2ho fM C A oa ta
magnification ×10. Treatment with DHA or saline was given at 3 h
after onset of stroke
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W h e nD H Aw a sg i v e n3ha f t e rM C A oo n s e t ,t h e
neurological scores were significantly improved on days 3
(p<0.01) and 7 (p<0.02; Fig. 3a). Also, initial smaller
infarcts were only localized to the striatum on day 1 and
were indistinguishable from normal tissues by day 7
(Fig. 3b). T2WI revealed large cortical and striatial
infarctions in saline rats that resolved over 7 days
(Fig. 3b). DHA yielded reduced T2 values (decreased
edema) within the lesion (p<0.002), and there were no
differences in T2 values for the contralateral tissues
(Fig. 3c). There was a difference in the ADC within the
infarcted lesion when comparing saline and DHA rats at
days 1, 3, and 7 after MCAo. The ipsilateral ADC value
was increased at days 1 and 7 (p<0.001). However, the
ADC in DHA was 21% lower at day 3. These dynamic
processes reflect repair mechanisms within the DHA-rat
lesion. Interestingly, ADC was increased in the DHA
contralateral lesion. Three-dimensional infarct volumes
were computed from T2WI (presented in Fig. 3d).
Series 3: Lipidomic Study
Because DHA is the precursor of NPD1 [11], we asked if
NPD1 synthesis occurs in the penumbra. Figure 4a–c shows
that DHA treatment potentiates NPD1 synthesis in the
penumbra 3 days after MCAo. We ascertained NPD1
synthesis in the penumbra by isolating and characterizing
17-HDHA. 17-HDHA reflects the presence of the unstable
17S-HpDHA. Since 17-HDHA and NPD1 were enhanced
in the penumbra by DHA, we concluded that active NPD1
synthesis occurs under these conditions. Figure 4d illus-
trates the release of DHA from the membrane followed by
the biosynthesis of NPD1.
Discussion
In this study, we have demonstrated that systemic admin-
istration of the DHA provides neurobehavioral recovery,
reduces brain infarction and brain edema, activates neuro-
protectin D1 synthesis in the penumbra, and promotes cell
survival when administered up to 5 h after focal cerebral
ischemia in rats.
DHA is an essential omega-3-fatty acid and is vital for
the proper brain functioning. It is also necessary for the
development of the nervous system, including vision.
Moreover, omega-3 fatty acids are part of a healthy diet
that helps lower the risk of heart disease. DHA belongs to
the omega-3 essential fatty acid family. As a consequence,
we depend on the dietary supply of DHA or of its
precursor, linonenic acid (18:3, n-3). DHA has potent
anti-inflammatory effects [5, 13, 19]. Since inflammation is
at the root of many chronic diseases, DHA treatment has
been widely demonstrated to have beneficial effects in
patients with coronary heart disease, asthma, rheumatoid
arthritis, osteoporosis, sepsis, cancer, dry eye disease, and
age-related macular degeneration [19].
Cerebral ischemia is characterized by a rapid accumulation
(withinminutes)offreefattyacids,includingarachidonicacid
(AA; 20:4 n-6) and DHA (22:6, n-3), due to increases in
intracellular calcium and activation of phospholipases [20].
This free pool of AA and DHA is then converted via active
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Fig. 2 a Coronal brain diagram showing locations of regions for cell
counts in cortex (1, 2, and 3), and striatum (S). b–d Number of GFAP-
positive astrocytes, ED-1 positive microglia cells, and NeuN-positive
neurons on day 7 after 2 h of MCAo. DHA or saline was given at 3 h
after onset of stroke. DHA treatment decreased ED-1, increased
NeuN- and GFAP-positive cell counts. Data are mean ± SEM.
Asterisk, significantly different from saline (p<0.05; repeated-
measures ANOVA followed by Bonferroni tests)
Transl. Stroke Res. (2011) 2:33–41 37enzymatic processes as well as free radical-mediated lipid
peroxidation into a cascade of activated pro- and anti-
inflammatory mediators, the makeup of which ultimately
drives the cell toward survival or programmed cell death.
Specifically, after hydrolysis, free (unesterified) DHA is
converted to form the stereospecific mediator NPD1 in a
series of reactions beginning with lipoxygenation by 15-
lipoxygenase-1 followed by epoxidation and hydrolysis
reactions (Fig. 4)[ 11]. NPD1 acts against apoptosis, promotes
cell survival, inhibits brain ischemia-reperfusion-mediated
leukocyte infiltration and pro-inflammatory gene expression,
promotes neurogenesis, attenuates edema formation, and
reduces stroke volume 48 h after MCAo onset [9, 21, 22].
Recently, we showed that administration of human serum
albumin complexed with DHA results in increased NPD1
production in the ipsilateral hemisphere, but not the contra-
lateral hemisphere. These results indicate that NPD1 synthesis
requires available DHA as well as harmful noxious stimuli
causing cellular damage [22].
Due to the challenges of treating patients in a timely
manner, an extension of the therapeutic window is
necessary to allow for broader appeal to clinicians treating
ischemic stroke victims. We asked if DHA could prolong
the therapeutic window in a setting of focal cerebral
ischemia. In our previous DHA dose–response study, we
showed that a low dose of DHA (3.5–7.0 mg/kg) has the
greatest effect on reducing infarct volume when adminis-
tered 3 h after MCAo onset [15]. We selected a dose in the
middle of the effective dose range (5 mg/kg) for our
therapeutic window study, which proved to be effective
even with a delay of treatment up to 5 h. Treatment with
DHA significantly improved the neurological score on
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38 Transl. Stroke Res. (2011) 2:33–41days 1, 2, 3, and 7 compared to vehicle rats even when
treatment was initiated as late as 5 h after onset of
ischemia. The effect of DHA was also demonstrated
clearly in the cortical (or penumbral region) of the infarct
by a significant 49% reduction of cortical infarct volume
when administered at 3 h, by 77% at 4 h, and by 71% at
5 h as compared to vehicle-treated rats. This effect was
associated with a reduction in edema (T2 normalization).
MRI studies showed that DHA treatment clearly reduced
the level of edema and significantly reduced total lesion
volumes compared to the saline treatment on days 1, 3, and 7.
Ischemic stroke intervention requires mixed cellular
protection of the penumbra. The term neuroprotection is
typically used to describe the protection of neurons from
the neurotoxic environment that occur during ischemia.
However, the complex processes that occur after stroke
require the targeting of multiple factors and cells, including
glia, vascular, and inflammatory cells. The histologic
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activation of the biosynthesis of NPD1. d Enzyme-mediated oxygen-
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brain ischemia-reperfusion. 15-Lipoxygenase-1 catalyzes the synthesis
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Transl. Stroke Res. (2011) 2:33–41 39distribution of molecular markers in the infarcted regions of
DHA-treated brains differed from saline-treated brains in
that DHA brains showed attenuated cellular death of both
astrocytes and neurons and fewer activated microglia, as
compared to saline-treated brains within the infracted
region. These results indicate that treatment with DHA
protects not only the neurons but astrocytes, which are
critical for the maintenance and protection of neurons via
the secretion of growth factors and other neurotrophic
mediators. Furthermore, DHA attenuated the activation of
microglia. Microglia are activated by cellular damage and
typically initiate an inflammatory response that results in
apoptosis and debris removal. This effect demonstrates
DHA's anti-inflammatory properties during cellular stress.
The next question we asked is whether DHA rescues the
ischemic penumbra. The ischemic penumbra (defined as
local cerebral blood flow (LCBF) of 20–40% of control)
forms an irregular rim around the ischemic core and tends to
be greatest in frontal and occipital cortex [23]. Although
reduced LCBF is a major factor responsible for necrotic
injury, other factors, including lipid peroxidation, inflamma-
tory responses, and development of brain edema, may also
contribute to either the severity or progression of penumbral
injury [24]. Stroke patients (44%) may have penumbral
tissue even after 18 h [25]. DHA has been shown to be
neuroprotective and is the precursor of NPD1, a novel lipid
mediator with powerful anti-apoptotic and pro-resolution
properties during oxidative stress and cellular damage.
Our lipidomic study demonstrated that DHA treatment
activates NPD1 synthesis in the salvageable penumbral
region of the infarct, which typically succumbs several
days after the initial ischemic insult due to the subse-
quent widespread inflammatory response elicited by
ischemia, rather than the actual ischemic episode. DHA
is converted through 15-lipoxygenase-1 into NPD1, a
potent mediator that evokes counteracting cell-protective,
anti-inflammatory, pro-survival repair signaling, includ-
ing the induction of anti-apoptotic Bcl-2 proteins and
inhibition of pro-apoptotic Bcl-2 proteins. Thus, NPD1
triggers activation of signaling pathway/s that modulate/s
pro-apoptotic signals, promoting cell survival as well as
inflammatory resolution [26]. Thus DHA/NPD1 is a
mechanism for protection in the ischemic brain penumbra,
amenable to further translational approaches.
Conclusion
We have shown that DHA administration provides neuro-
behavioral recovery, reduces brain infarction and brain
edema, activates neuroprotectin D1 synthesis in the
penumbra, and promotes cell survival when administered
up to 5 h after focal cerebral ischemia in rats.
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